The Current Suspension/Debarment Landscape
Client Alert | less than 1 min read | 05.25.17
With the federal suspension/debarment processes becoming more collaborative, contractors find themselves facing new agencies and new (and, generally, longer-lasting) procedures when dealing with suspending and debarring officials. David Robbins, Angela Styles & Peter Eyre cover the most recent changes in federal suspension, debarment, and proactive disclosure practice in Not Your Grandfather’s Suspension & Debarment: How Contractors Can Prepare For and Defend Against Today’s Exclusions.
Contacts
Insights
Client Alert | 2 min read | 09.18.25
On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”
Client Alert | 3 min read | 09.17.25
Client Alert | 4 min read | 09.17.25
Client Alert | 5 min read | 09.16.25
Bucking the Odds: Why Technology Companies Should Embrace Software Patents Today
